Adaptive Biotechnologies Corporation - Common Stock (ADPT)

Competitors to Adaptive Biotechnologies Corporation - Common Stock (ADPT)

GRAIL, Inc.

GRAIL is focused on early detection of cancer through multi-cancer early detection (MCED) tests, competing with Adaptive's immuno-oncology testing. While Adaptive is using sequencing to understand the immune repertoire and response, GRAIL is applying similar technological advancements specifically tailored to discovering cancers at an early stage. GRAIL benefits from substantial venture backing and partnerships, giving it a strong position in the early cancer detection niche. Adaptive, however, holds a unique proposition in leveraging immune response profiling that GRAIL does not directly address.

Guardant Health, Inc. 

Guardant Health competes primarily in the space of liquid biopsy and cancer diagnostics, similar to Adaptive's focus on immune profiling and diagnostics. Both companies are leveraging advanced sequencing techniques to provide valuable insights into patient health, with Adaptive concentrating more on immune responses. Guardant's specialized focus on cancer genomics and established test offerings in the oncology market create a strong competitive stance. However, Adaptive's unique immune-driven approach presents differentiated competition, especially in the context of autoimmune diseases.

Illumina, Inc. 

Illumina and Adaptive Biotechnologies are both key players in the genomics space, focusing on next-generation sequencing technologies. Illumina dominates the sequencing market with its comprehensive array of platforms, making genomic analysis accessible at scale. Adaptive, on the other hand, specializes in using sequencing data to provide insights into immune-mediated diseases. While Adaptive leverages Illumina's technology, Illumina's market presence and wide adoption give it a competitive edge in the broader genomics landscape.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific competes in the life sciences sector with a broad range of products including reagents, instruments, and services crucial for genomic research and diagnostics. While Thermo Fisher offers tools that Adaptive may use in its assays and testing, Adaptive differentiates itself through its specific focus on immune repertoire and T-cell sequencing. Thermo Fisher's extensive resources and broad reach in laboratories provide them an advantageous position in the marketplace, but Adaptive's focused niche creates barriers allowing it to provide specialized products.